Imipenem levels are not predictable in the critically ill patient

被引:43
作者
Belzberg, H
Zhu, J
Cornwell, EE
Murray, JA
Sava, J
Salim, A
Velmahos, GC
Gill, MA
机构
[1] Los Angeles Cty & Univ So Calif, Ctr Med, Dept Surg, Los Angeles, CA 90033 USA
[2] Univ So Calif, Sch Pharm, Los Angeles, CA 90089 USA
[3] Johns Hopkins Univ Hosp, Dept Surg, Baltimore, MD 21287 USA
来源
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE | 2004年 / 56卷 / 01期
关键词
septic shock; systemic inflammatory distress syndrome; sepsis therapeutic levels; imipenem; volume of distribution;
D O I
10.1097/01.TA.0000056164.26493.28
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Critically ill patients often demonstrate extremely unusual volumes of distribution (Vd) and half-lives (t(1/2)) of drugs. Imipenem is a widely used antibiotic in critically ill patients. Methods: We performed high-performance liquid chromatography analysis of imipenem in samples from 50 critically ill patients treated with either 500 or 1,000 mg. Results: Peak imipenem levels varied from 1.56 mug/mL to 58.8 mug/mL. Trough levels varied between 0.0 mug/mL and 15.62 mug/mL. Only 54% of patients maintained a trough level greater than 4 mug/mL. Both the Vd and the t(1/2) of imipenem were much greater than observed in other patient populations. Conclusions: The pharmacokinetic activity of imipenem in critically ill patients is different from that in other patient populations. There is a very weak correlation between dosage and serum concentrations. Therapeutic failures of imipenem may be because of unpredictable pharmacodynamics (Vd and t(1/2)) in critically ill surgical patients.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 19 条
[1]   COMPUTATION OF MODEL-INDEPENDENT PHARMACOKINETIC PARAMETERS DURING MULTIPLE DOSING [J].
BAUER, LA ;
GIBALDI, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (08) :978-979
[2]   PHARMACOKINETIC EVALUATION OF IMIPENEM COMBINED WITH CILASTATIN IN CYSTIC-FIBROSIS [J].
BERGAN, T ;
MICHALSEN, H ;
MALMBORG, AS ;
PEDERSEN, SS ;
PRESSLER, T ;
STORROSTEN, OT ;
STRANDVIK, B .
CHEMOTHERAPY, 1993, 39 (06) :369-373
[3]   SEPSIS SYNDROME - A VALID CLINICAL ENTITY [J].
BONE, RC ;
FISHER, CJ ;
CLEMMER, TP ;
SLOTMAN, GJ ;
METZ, CA ;
BALK, RA .
CRITICAL CARE MEDICINE, 1989, 17 (05) :389-393
[4]   IMIPENEM PHARMACOKINETICS IN PATIENTS WITH BURNS [J].
BOUCHER, BA ;
HICKERSON, WL ;
KUHL, DA ;
BOMBASSARO, AM ;
JARESKO, GS .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (02) :130-137
[5]   IMIPENEM CILASTATIN - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY [J].
CLISSOLD, SP ;
TODD, PA ;
CAMPOLIRICHARDS, DM .
DRUGS, 1987, 33 (03) :183-241
[6]   Aminoglycoside levels in critically ill surgical patients: The implications of physiologic criteria of sepsis [J].
Cornwell, EE ;
Belzberg, H ;
Berne, TV ;
Kern, JW ;
Henriques, G ;
Asensio, JA ;
Demetriades, D .
SOUTHERN MEDICAL JOURNAL, 1997, 90 (01) :33-36
[7]   Pharmacokinetics of aztreonam in critically ill surgical patients [J].
Cornwell, EE ;
Belzberg, H ;
Berne, TV ;
Gill, MA ;
Theodorou, D ;
Kern, JW ;
Yu, W ;
Asensio, J ;
Demetriades, D .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (05) :537-540
[8]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[9]   MULTIPLE-DOSE PHARMACOKINETICS OF IMIPENEM-CILASTATIN [J].
DRUSANO, GL ;
STANDIFORD, HC ;
BUSTAMANTE, C ;
FORREST, A ;
RIVERA, G ;
LESLIE, J ;
TATEM, B ;
DELAPORTAS, D ;
MACGREGOR, RR ;
SCHIMPFF, SC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (05) :715-721
[10]   PHARMACOKINETICS OF IMIPENEM IN PATIENTS UNDERGOING MAJOR COLON SURGERY [J].
ERTTMANN, M ;
KRAUSSE, R ;
ULLMANN, U .
INFECTION, 1990, 18 (06) :367-371